Chronic Obstructive Pulmonary Disease (COPD) is a disease that is often overlooked. Although it is quickly becoming a leading cause of death across the globe, current management of COPD is largely aimed at alleviating symptoms only. Once conventional treatments have failed, many COPD patients are left forgotten and marginalized with few answers. As advocates for these patients, Lung Health Institute’s Dr. Jack Coleman Jr., M.D., FACS and Melissa Rubio, Ph.D., APRN embarked on the organization’s largest study to date, and the results were presented at the Mayo Clinic Symposium on Regenerative Medicine & Surgery 2018 in Scottsdale, AZ. The results of the study, evaluating more than 2500 patients with chronic lung disease, showed improvement in both pulmonary lung function and quality of life after just three months with sustained results at the six and twelve month mark.
The abstract, “Effect of Regenerative Medicine Interventions on Chronic Lung Disease in 2782 Patients,” evaluated 2782 patients treated with regenerative medicine-based treatment for chronic lung disease, including Chronic Adult Asthma (13 patients), COPD (2316 patients) and Interstitial Lung Disease (ILD) (453 patients). ILD is a disease of chronic inflammation as the primary cause of damage to the tissue, similar to COPD. However, unlike COPD, ILD has resultant fibrosis, making progression from diagnosis to death more rapid.
During the study, patients underwent cellular therapy with their own cells harvested from peripheral blood or bone marrow with mesenchymal stem cells.
Both quantitative and qualitative results were collected during the months following treatment, using:
- FEV1% – the percentage of predicted Forced Expiratory Volume at 1 second. FEV1 is a direct reflection of the severity of obstruction and is the standard of care for determining a patient’s COPD GOLD Stage. As COPD worsens, FEV1 decreases.
- Clinical COPD Questionnaire (CCQ) – a 10-item Likert-type scale that measures quality of life based on symptom, functional status and mental status domains on a scale. It was administered to all patients at pre-treatment and again at 3 months, 6 months and 12 months post-treatment by phone.
Specifically, after just three months: 56 percent of patients had improvement in their FEV1, and more than 70 percent of patients reported a clinically meaningful improvement via their CCQ. Additionally, patients continued to see improvement a year later – with 57 percent of the remaining patient sample continuing to report an improvement in quality of life per their CCQ scores.
These exciting new results point to the promising future of regenerative medicine for those with chronic lung disease. However, more research is needed to further understand and effectively treat these complex, heterogeneous diseases. Lung Health Institute is committed to continuing to study and advance innovative and novel therapies that others in the industry have forgotten.
For more information on this study and Lung Health Institute, visit lunginstitute.com/dev.